Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AHFS | American Hospital Formulary Service |
| ASP | Average sales price |
| CGI-C | Clinician Global Impression of Change |
| CGI-S | Clinician Global Impression of Severity |
| CI | Confidence interval |
| EMA | European Medicines Agency |
| FDA | United States Food and Drug Administration |
| HRQoL | Health-related quality of life |
| ISSVA | International Society for the Study of Vascular Anomalies |
| ITT | Intent-to-treat |
| LM | Lymphatic malformation |
| LMC | Lymphatic malformation with a cutaneous component |
| LMF | Lymphatic Malformation Function |
| mLM | Microcystic lymphatic malformation |
| mLM-IGA | Microcystic Lymphatic Malformation Investigator Global Assessment |
| mLM-MCSS | Microcystic Lymphatic Malformation Multi-Component Static Scale |
| mTOR | Mammalian target of rapamycin |
| mTORC1 | Mammalian target of rapamycin complex 1 |
| mTORC2 | Mammalian target of rapamycin complex 2 |
| NCT | ClinicalTrials.gov study identifier |
| NDA | New Drug Application |
| PGI-C | Patient Global Impression of Change |
| PGI-S | Patient Global Impression of Severity |
| PI3K | Phosphatidylinositol 3-kinase |
| PIK3CA | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| PNDS | Protocole national de diagnostic et de soins |
| SAE | Serious adverse event |
| SELVA | Phase 3 study of QTORIN rapamycin in microcystic lymphatic malformations |
| TEAE | Treatment-emergent adverse event |
| TRAE | Treatment-related adverse event |
| TSQM-9 | Treatment Satisfaction Questionnaire for Medication, nine-item version |
| WAC | Wholesale acquisition cost |